Finally, several phase I clinical trials have been designed to treat patients with Gal3 inhibitors together with immunotherapy in different tumor types, including, non-small cell lung cancer, squamous cell head and neck cancers [105], and melanoma [104], the latter of which has given promising results. This evidence concerns the gene LGALS3 and melanoma.